[1] 曾程,杨丹,杜荣旭,等.局部晚期不可手术食管癌同步放化疗联合尼妥珠单抗的初步临床分析[J].中华放射肿瘤学杂志,2021,30(4):353-356.
[2] Mayanagi S,Irino T,Kawakubo H,et al.Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer[J].Ann Gastroenterol Surg.2019,3(3):269-275.
[3] Terada M,Hara H,Daiko H,et al.Phase Ⅲ study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus(JCOG1510:TRIANgLE)[J].Jpn J Clin Oncol.2019,49(11):1055-1060.
[4] 吴小源,杨原源,邢文群,等.局部晚期食管鳞癌术前同期放化疗疗效及预后因素分析[J].中华放射肿瘤学杂志,2020,29(5):337-341.
[5] 方文涛. 通过食管癌TNM新分期(第八版)解读2017年NCCN食管鳞癌诊疗指南[J].中华胃肠外科杂志,2017,20(10):1122-1126.
[6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90.
[7] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[8] 戴婷婷,王万伟,仝宇梭,等.多西他赛联合顺铂同步放化疗和单纯放疗治疗老年非手术食管鳞癌的临床疗效分析[J].实用癌症杂志,2019,34(3):417-420.
[9] 刘良忠,李小红,彭科瑜,等.调强放疗同步多西他赛联合奥沙利铂化疗治疗Ⅲ/Ⅳ期食管癌的临床研究[J].实用医学杂志,2019,35(24):3808-3812.
[10] 黄超,金锷.替吉奥、氟尿嘧啶分别和多西他赛联合对高龄晚期胃癌患者的疗效比较[J].中国老年学杂志,2020,40(17):3638-3642.
[11] Sakai M,Sohda M,Saito H,et al.Concurrent Chemoradiotherapy With Docetaxel,Cisplatin,and 5-Fluorouracil(DCF-RT)vs.Cisplatin and 5-Fluorouracil(CF-RT)for Patients With Unresectable Locally Advanced Esophageal Cancer in a Real-world Clinical Setting[J].Anticancer Res.2021,41(4):2141-2145.
[12] 朱林,袁高峰,胡筱,等.白蛋白紫杉醇联合顺铂方案同步放化疗治疗局部晚期食管癌的临床观察[J].临床肿瘤学杂志,2020,25(10):916-920.
[13] 张雪娣,牛红卫,张秀娟.多西他赛和顺铂化疗联合同步调强放疗治疗食管癌术后复发的效果及对其血清肿瘤标志物含量的影响[J].临床医药实践,2020,29(10):766-768.
[14] Chan WL,Choi CW,Wong IY,et al.Docetaxel,Cisplatin,and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma[J].Ann Surg Oncol.2023,30(2):861-870.
[15] 梁丽冰,王洪乾,高扬,朱均强.DP与PF方案化疗同步调强适形放疗治疗局部中晚期食管鳞癌的回顾性研究[J].右江医学,2020,48(6):437-442. |
2024, Vol. 44 
